BRD4 and breast cancer: The most studied BRD4 inhibitor in BC is JQ1, which shows effective anti-cancer functions and synergistic effects with other drugs, such as docetaxel, vinorelbine, cisplatin, carboplatin (Pérez-Peña et al., 2016), fulvestrant (Feng et al., 2014), lapatinib (Stuhlmiller et al., 2015), olaparib (Yang et al., 2017), SAHA (Zeng et al., 2016), mocetinostat (Borbely et al., 2015), volasertib (Sahni et al., 2017), everolimus (Bihani et al., 2015; Vázquez et al., 2017), rapamycin, torin (Marcotte et al., 2016), trametinib (Zawistowski et al., 2017), and GDC-0941 (Stratikopoulos et al., 2015).